Jounce Therapeutics, Inc.
DelistedCIK 1640455fmd_0QEQDS7A1NTPNM9CM2DZGHGF7SManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Dec 31, 2022, 29 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 22 | 35 | 68 | 70 | 67 | 79 | 89 | 103 |
| Total operating expenses | 30 | 52 | 91 | 96 | 95 | 107 | 118 | 134 |
| Operating income | (30) | (14) | (19) | (31) | 53 | (45) | (91) | (52) |
| Other non-operating income (expense) | 2 | 1 | 3 | 4 | 4 | 1 | 0 | 1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (29) | (14) | (16) | (27) | 57 | (44) | (91) | (51) |
| Net income to common shareholders | (38) | (23) | (17) | (27) | – | – | – | – |